# A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer

> **NCT02232633** · PHASE2 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 45 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Cholangiocarcinoma

## Interventions

- **DRUG:** BBI503

## Key facts

- **NCT ID:** NCT02232633
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2017-12-14
- **Final completion:** 2017-12-14
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2023-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02232633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02232633, "A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02232633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*